Five-Year Clinical Experience with the Omniscience Cardiac Valve |
| |
Authors: | Richard DeWall L Conrad Pelletier Antonio Panebianco George Hicks Benjamin Schuster Raoul Bonan Jean-Paul Martineau Luke Yip |
| |
Institution: | Kettering Medical Center, Dayton, OH, Institut de Cardiologie de Montreal, Montreal, PQ, Canada Lehigh Valley Hospital, Allentown, PA |
| |
Abstract: | Clinical data on the Omniscience cardiac valve prosthesis (sizes 19 to 31 mm) were obtained from 326 patients (155, aortic valve replacement AVR]; 125, mitral valve replacement MVR]; and 46, double-valve replacement) during a five-year period (650 patient-years) with 96% accountability. Mean age was 56 ± 12 years, and 40% (130) of the patients were 61 years old or older. Thirty-one percent (101) had prior or concomitant coronary artery bypass grafting procedures, 9% (28) had a previous malfunctioning prosthesis, and 17% (57) had other cardiac surgical procedures. Eighty percent were in New York Heart Association (NYHA) Functional Class III or IV preoperatively. Early mortality was 10% (34). Five-year actuarial thrombus-free rate is 96% for patients who underwent AVR and 95% for patients having MVR. Postoperatively, 89% (172/193) were in NYHA Class I or II, and 84% (163/193) improved by at least one Functional Class. A significantly high proportion of the postoperative hematological values fall within normal ranges: red blood cell count, 94% (176/187); hematocrit, 88% (166/188); and hemoglobin, 93% (176/190). Ninety-eight percent (287/292) are free from clinical anemia. Four of the 5 patients with clinical anemia had a preoperative history of this condition. Levels of lactic dehydrogenase in 3 patients suggested the probable presence of clinically significant hemolysis, although all 3 have normal hematological values. Actuarial five-year survival for patients who underwent AVR or MVR are similar (82% and 80%, respectively), indicating satisfactory and comparable levels of safety and performance. Based on the duration of the study and the absence of restrictive selection criteria, which would eliminate high-risk patients, these clinical data demonstrate a reliable degree of safety and performance for this prosthesis. |
| |
Keywords: | Address reprint requests to Dr DeWall 421 Thornhill Rd Dayton OH 45419 |
本文献已被 ScienceDirect 等数据库收录! |
|